FDA — authorised 4 February 2004
- Application: NDA021462
- Marketing authorisation holder: LILLY
- Local brand name: ALIMTA
- Indication: POWDER — INTRAVENOUS
- Status: approved
FDA authorised Pemetrexate on 4 February 2004
Yes. FDA authorised it on 4 February 2004.
LILLY holds the US marketing authorisation.